Cyclopharm (ASX:CYC) has reached a significant milestone in the global adoption of its flagship lung imaging technology, with Technegas formally recognised as a preferred ventilation agent in a newly released international clinical guideline for lung imaging.
The recognition comes through a draft Procedure Standard and Guideline for Ventilation–Perfusion (V/Q) Pulmonary Scintigraphy, released for public consultation by the leading US peak body for nuclear medicine imaging. The guideline explicitly states that, for most clinical conditions, including the assessment of pulmonary embolism, technetium-based agents are typically used, with Technegas generally preferred when available.
The guideline has been developed by a multinational expert panel and represents a rare and highly authoritative collaboration between the US Society of Nuclear Medicine and Molecular Imaging, the American College of Nuclear Medicine, and the European Association of Nuclear Medicine, alongside experts from Australia and Canada. While released as a draft for consultation, the document is noted to have already undergone a thorough clinical consensus process and extensive review, with final publication expected in the coming months.
Inclusion in US clinical guidance represents a material inflection point for Technegas in the United States market. The guideline positions Technegas as a clinical advancement that has enhanced the diagnostic accuracy and utility of lung scintigraphy, reflecting more than a decade of international progress in lung imaging technologies and practice since the last comprehensive US-aligned update in 2012.
Cyclopharm said it expects the guideline’s endorsement to support broader institutional adoption of Technegas across the US healthcare system, driving increased utilisation and faster integration into standard clinical workflows within hospitals and imaging centres. Such consensus-based guidelines are widely regarded as foundational references for clinicians and play a critical role in shaping durable changes in clinical behaviour, procurement decisions, and reimbursement pathways.
Beyond pulmonary embolism, the draft guideline highlights the expanding role of Technegas-enabled imaging across a wide range of clinical indications. These include chronic thromboembolic pulmonary hypertension, chronic obstructive pulmonary disease, asthma, post-pulmonary embolism follow-up, lung transplantation assessment, radiotherapy planning, and regional lung function analysis. The document also acknowledges the evolution of lung scintigraphy through advanced SPECT and SPECT/CT imaging, artificial intelligence, and functional ventilation agents such as Technegas.
Cyclopharm Chief Executive Officer James McBrayer said the guideline provides clinicians with evidence-based recommendations for performing and interpreting lung imaging studies, noting that international multi-society consensus guidelines are uncommon and carry a unique level of authority within clinical practice. When combined with peer-reviewed clinical evidence, such guidelines sit at the top of the evidence hierarchy required to enable lasting changes in clinical adoption and healthcare system decision-making.